Anadys Pharmaceuticals, Inc.
http://www.anadyspharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Anadys Pharmaceuticals, Inc.
Jazz Trumpets 2025 Strategy With Neurology, Oncology Focus
The company laid out plans at J.P. Morgan to reach revenues of $5bn by 2025, focusing on already marketed products and its pipeline plans.
J.P. Morgan Day 4: Preparing For The Year Ahead
Daily notebook from the virtual J.P. Morgan Healthcare Conference: Updates from Galapagos, Ipsen, LG Chem, Hanmi and Fosun; experts discuss deal and financial outlook at Biotech Showcase, plus the impact of RMAT and the changing landscape for rare diseases.
Deal Watch: J&J Begins 2022 With Trio Of Technology Alliances
Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.
Coronavirus Update: India Approves Multiple New Vaccines
India has issued emergency approvals for a number of new vaccines and extended eligible age groups for others, while developers of potential drug therapies in China see both gains and setbacks.